Long-term survival after immunochemotherapy for juvenile colon cancer with peritoneal dissemination A case report

Oncology Reports

Volumn 7, Issue 6, 2000, Pages 1343-1347

  Mukai, Masaya ^a,b   Tokunaga, Nobuhiro ^a   Yasuda, Seiei ^a   Mukohyama, Sayuri ^a   Kameya, Takehiko ^a   Ishikawa, Kenji ^a   Iwase, Hirotada ^a   Suzuki, Toshiyuki ^a   Ishida, Hideki ^a   Sadahiro, Sotaro ^a   Makuuchi, Hiroyasu ^a  

^a TOKAI UNIVERSITY   (Japan)

^b TOKAI UNIVERSITY HOSPITAL   (Japan)

Author keywords

Colorectal cancer; Immunochemotherapy; Juvenile colon cancer; Long term survival; Peritoneal dissemination; Tumor dormancy therapy

Indexed keywords

1 UFT PROTOCOL; 1-UFT PROTOCOL; ANTINEOPLASTIC AGENT; KRESTIN; PROTEOGLYCAN; PS-K; TEGAFUR; URACIL;

ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; CASE REPORT; COLON TUMOR; HUMAN; MALE; METASTASIS; PALLIATIVE THERAPY; PATHOLOGY; PERITONEUM TUMOR;

ADENOCARCINOMA; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; HUMANS; MALE; PALLIATIVE CARE; PERITONEAL NEOPLASMS; PROTEOGLYCANS; TEGAFUR; URACIL;

EID: 0034321634     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.7.6.1343     Document Type: Article

References (10)

1. Okuno M, Ikehara T, Nagayama M, Sakamoto K, Kato Y and Umeyama K: Colorectal carcinoma in young adults. Am J Surg 154: 264-268, 1987.
2. Mitomi T, Tsuchiya S, Iijima N, Aso K, Suzuki K. Nishiyama K, Amano T, Takahashi T, Murayama N, Oka H. Oya K, Noto T and Ogawa N: Randomized controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. Dis Colon Rectum 35: 123-130, 1992.
3. Nakazato H, Koike A, Saji S, Ogawa N and Sakamoto J: Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Lancet 343: 1122-1226, 1994.
4. Tsukagoshi S, Hashimoto Y, Fujii G, Kobayashi H, Nomoto K and Orita K: Krestin (PSK). Cancer Treat Rev 11: 131-155, 1984.
5. Ho DW, Pazdur R, Covington W, Brown N, Huo YY, Lassere Y and Kuritani J: Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2′-tetrahydrofuryl)-5-fluorouracil. Clin Cancer Res 4: 2085-2088, 1998.
6. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA and Fryer JG: A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a mid-Atlantic oncology program study. J Clin Oncol 17: 425-432, 1989.
7. Stewart THM: Immune mechanisms and tumor dormancy. Medicina 56 (Suppl 1): 74-82, 1996.
8. Urushizaki I: Concept of tumor dormancy therapy. Biotherapy (in Japanese with English abstract) 12: 923-932, 1998.
9. Sadahiro S, Mukai M, Tokunaga N, Tajima T, Makuuchi H, Yoshida, Okabe H, Uchida J, Takeda S and Unemi N: Preliminary study on the optimal dosage schedule for oral Tegafur/uracil (UFT) chemotherapy. Int J Clin Oncol 3: 7-12, 1998.
10. Mukai M, Noto T, Yasuda S, Tokuda Y, Hanaue H, Tajima T, Mitomi T, Tsutsumi Y and Osamura Y: An autopsy case of anticancer drug induced gastroenterocolitis following effective chemotherapy. J Jpn Soc Cancer Ther (in Japanese with English abstract) 28: 942-948, 1993.